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Objectives The purpose of this study was to clarify the impact of sex-related differences in transcatheter aortic valve im-
plantation (TAVI) for high-risk patients with severe aortic stenosis.
Background Although TAVI is becoming a mature technique, the impact of sex differences remains unclear.
Methods The TAVI patients were included prospectively in a dedicated database from October 2006. The proportion of
women (n  131) was similar to that of men (n  129). The Edwards valve (85.4%) and CoreValve (14.6%)
were used through the transfemoral (65.0%), subclavian (3.1%), or transapical (31.9%) approach. All events
were defined according to Valve Academic Research Consortium criteria.
Results Age was similar (83.1  6.3 years), but women had less coronary and peripheral disease, less previous cardiac
surgery, higher ejection fraction, and lower EuroSCORE (European System for Cardiac Operative Risk Evaluation
[22.3  9.0% vs. 26.2  13.0%, p  0.005]). Minimal femoral size (7.74  1.03 mm vs. 8.55  1.34 mm,
p  0.001), annulus size (20.9  1.4 vs. 22.9  1.7 mm, p  0.001), and valve size (23.9  1.6 mm vs. 26.3 
1.5 mm, p  0.001) were smaller in women. Device success was similar (90.8% vs. 88.4%, p  0.516) despite
more frequent iliac complications (9.0% vs. 2.5%, p  0.030). Residual mean aortic pressure gradient (11.6 
4.9 vs. 10.9  4.9, p  0.279) was also similar. The 1-year survival rate was higher for women, 76% (95% confi-
dence interval: 72% to 80%), than for men, 65% (95% confidence interval: 60% to 69%); and male sex (hazard
ratio: 1.62, 95% confidence interval: 1.03 to 2.53, p  0.037) was identified as a predictor of midterm mortality
by Cox regression analysis.
Conclusions Female sex is associated with better baseline clinical characteristics and improved survival, and is identified as
a predictor of midterm survival after TAVI. (J Am Coll Cardiol 2012;59:566–71) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.877Although sex-related differences in cardiovascular disease
have been explored for a long time, only a few studies have
been conducted to clarify sex differences in patients with
aortic stenosis (AS) and the impact of sex on clinical
outcomes after surgical aortic valve replacement (SAVR)
(1–4). Certain studies have shown an increased short-term
mortality rate (1,5), and female sex has been identified by
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Risk Evaluation) as a predictor of perioperative mortality
after cardiac surgery. Other studies have shown either better
long-term survival in females (2,4) or no sex differences (3).
Transcatheter aortic valve implantation (TAVI) has re-
cently emerged as a promising therapeutic option for pa-
tients with severe symptomatic AS, who are ineligible for or
at high risk with conventional SAVR (6). However, there is
a paucity of data describing sex-related differences in TAVI.
In contrast with percutaneous coronary intervention stud-
ies in which women only account for 15% to 20% of
patients, women constitute 50% of patients eligible for
TAVI, which guarantees the statistical relevance of analyses
carried out in this context. Moreover, the cost effectiveness
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February 7, 2012:566–71 Sex-Related Differences in TAVIof TAVI procedures in women may be further enhanced by
their longer life expectancy.
The purpose of this study was to highlight sex differences
in clinical presentation and to identify predictors of midterm
mortality in a large cohort of TAVI patients, based on the
newly developed Valve Academic Research Consortium
(VARC) criteria (7).
Methods
Study population and design. Between October 2006 and
December 2010, consecutive high-risk patients with severe
AS treated with TAVI at our institution were prospectively
included in our database. Patients with symptomatic severe
AS were considered candidates for TAVI if they had a
logistic EuroSCORE 20%, or if surgery was deemed high
risk, as previously described (8). The decision to proceed
with TAVI was discussed by a dedicated heart team
including experienced clinical and interventional cardiolo-
gists, cardiovascular surgeons, and anesthesiologists.
Valve and approach site selection strategy. Patients were
selected to undergo TAVI by the transfemoral approach or
alternative approaches depending on iliofemoral access (8).
The valve prosthesis was selected according to the annulus
size; the Edwards valve (Edwards Lifesciences, Irvine,
California) was used in patients with an 18 to 24.5 mm
annulus size, and the CoreValve (Medtronic, Santa Rosa,
California) was used for 20 to 26.5 mm size (Fig. 1). The
Edwards valve was predominantly used in patients with a
20 to 24.5 mm annulus amenable to treatment with either
type of valve. The transapical and transsubclavian ap-
proaches were used as alternatives to unsuitable iliofem-
oral approach routes for the Edwards valve and Core-
Valve, respectively.
Figure 1 Valve Bioprosthesis Selection Strategy
Patients were selected to undergo transcatheter aortic valve implantation (TAVI) by
the transfemoral (TF) approach or alternative approaches depending on the iliofem-
oral access. The valve prosthesis was selected according to the annulus size; the
Edwards valve was used in patients with an 18 mm to 24.5 mm annulus size and
the CoreValve for 20 mm to 26.5 mm. CT  computed tomography; FA  femoral
artery; SFAR  sheath outer diameter/femoral artery ratio; TA  transapical;
TEE  transesophageal echocardiography; TS  transsubclavian.yProcedures. The technical as-
pects of the TAVI procedures
have been previously described
(9,10). The majority of patients
were pre-treated with aspirin 75
to 160 mg and clopidogrel 75 mg
daily. Intravenous heparin was
administered to keep a target ac-
tivated clotting time (ACT) of
250 to 300 s. General anesthesia
was used for all transapical and
transsubclavian cases and for ini-
tial transfemoral procedures. Lo-
cal anesthesia with mild sedation
was introduced later for the
transfemoral cases.
Post-procedural care. All pa-
tients were monitored in the in-
tensive care unit for at least 24 h.
Dual-antiplatelet therapy (aspi-
rin 160 mg, clopidogrel 75 mg) was administered for 3 to 6
months, and thereafter aspirin was continued indefinitely.
Follow-up. After TAVI, all patients were assessed by a
physician at 1, 3, 6, and 12 months post-operatively and
thereafter annually. Additional follow-up data were collected
through telephone interviews and contact with patients’ family
physicians, except for 1 case lost during follow-up.
Endpoint definitions. The primary endpoints of this study
were device success, all-cause mortality (30-day and midterm)
and combined 30-day safety endpoints as defined by the
VARC (7). Device success was defined as successful vascular
access, delivery, and deployment of 1 prosthesis, and correct
position and performance of the prosthetic valve.
Statistical analysis. Quantitative variables are expressed as
mean  SD, and qualitative variables using numbers and
percentages. Comparison of quantitative variables was per-
formed with an unpaired Student t test or Wilcoxon
rank-sum test. The chi-square test or Fisher’s exact test was
used to compare qualitative variables. A Cox regression
analysis was performed to determine the predictors for
midterm mortality. Statistical significance was defined as
p  0.05. The data were analyzed with PASW statistics
version 17.0 (SPSS, Chicago, Illinois).
Results
A total of 260 patients underwent TAVI using both
commercially available bioprostheses: the Edwards valve in
222 cases (Cribier-Edwards [n  13], Edwards-SAPIEN
[n  107], or SAPIEN-XT [n  102], Edwards Life-
ciences), and the third-generation CoreValve revalving
ystem in 38 (Medtronic).
atient and procedural characteristics. Of 260 patients,
31 were women (Table 1). Female patients tended to be
lder than male patients (83.8  5.9 years vs. 82.4  6.5
Abbreviations
and Acronyms
AS  aortic stenosis
BMI  body mass index
BSA  body surface area
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
SAVR  surgical aortic
valve replacement
TAVI  transcatheter aortic
valve implantation
VARC  Valve Academic
Research Consortiumears, p  0.080), with less coronary artery disease (48.9%
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Sex-Related Differences in TAVI February 7, 2012:566–71vs. 79.1%, p  0.001), less previous cardiac surgery (13.7%
vs. 26.4%, p  0.011), and less peripheral artery disease
(26.7% vs. 40.3%, p  0.020), whereas left ventricular
ejection fraction (LVEF) was higher in women compared to
men (53.5  12.9% vs. 47.1  14.6%, p  0.001). Finally,
ogistic EuroSCORE was lower in women than in men
22.3  9.1% vs. 26.2  13.0%, p  0.005).
Echocardiography showed a similar aortic valve area
(0.59  0.17 cm2 vs. 0.61  0.13 cm2, p  0.248) but a
arger valve area index (0.35  0.10 cm2/m2 vs. 0.33  0.07
cm2/m2, p  0.037) in women who had a smaller body
surface area (BSA [1.65  0.17 vs. 1.85  0.16 m2, p 
0.001]) compared to women with a larger BSA. The
annulus size was also smaller (20.9 1.4 mm vs. 22.9 1.7
mm, p  0.001) as was the bioprosthesis size (23.9  1.6
mm vs. 26.3  1.5 mm, p  0.001).
The Edwards valve was used in the majority (85.4%) of
the whole cohort, and more frequently in women compared
to men (91.6% vs. 79.1%, p  0.005) (Table 2). The
minimal femoral artery diameter (7.74  1.03 mm vs.
8.55  1.34 mm, p  0.001) and femoral calcification score
(0.37  0.57 vs. 0.77  0.75, p  0.001) were smaller in
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Total (N  260)
Age, yrs 83.1 6.3
BSA, m2 1.75 0.19
BMI, kg/m2 25.7 4.5
Diabetes mellitus 61 (23.5%)
Hyperlipidemia 126 (48.5%)
Hypertension 184 (70.8%)
Current smoker 17 (6.5%)
NYHA functional class III or IV 220 (84.6%)
Coronary artery disease 166 (63.8%)
Previous MI 38 (14.6%)
Previous PCI 79 (30.4%)
Previous cardiac surgery 52 (20.0%)
Peripheral artery disease 87 (33.5%)
Cerebrovascular disease 33 (12.7%)
COPD 97 (37.3%)
eGFR, ml/min 52.0 25.2
eGFR 60 ml/min 174 (67.7%)
Logistic EuroSCORE, % 24.3 11.4
Aortic valve area, cm2 0.60 0.15
Aortic valve area index, cm2/mm2 0.34 0.09
Mean pressure gradient, mm Hg 47.6 18.1
LVEF, % 50.4 14.1
LVEF 40% 77 (29.6%)
Aortic annulus size, mm 21.9 1.8
Ascending aorta size, mm 34.7 4.3
Pulmonary hypertension 75 (28.8%)
Aortic regurgitation (0–4) 0.83 0.71
Mitral regurgitation (0–4) 0.98 0.72
Values are mean  SD or n (%).
BMI body mass index; BSA body surface area; COPD chronic
EuroSCORE European System for Cardiac Operative Risk Evaluation;
New York Heart Association; PCI  percutaneous coronary interventioomen compared to men. (evice success, periprocedural complications, and outcome.
evice success was achieved in 89.6% of the whole
ohort, without significant sex-related differences (90.8%
s. 88.4%, p  0.516). Although there was no significant
ifference in the rate of major vascular complications
etween sexes (11.5% vs. 9.3%, p  0.570), iliac compli-
ations were more frequent in women compared to men
9.0% vs. 2.5%, p  0.030) (Table 3). Conversion to
pen-heart surgery was required in 7 cases, 4 in female
atients (2 valve migration, 1 annulus rupture, and 1
ailed subclavian access) and 3 in male patients (1 valve
igration, 1 annulus rupture, and 1 post-procedural
evere AR [3.1% vs. 2.3%, p  0.718]).
At discharge, the mean aortic pressure gradient was
imilar in both groups (11.6  4.9 vs. 10.9  4.9, p 
0.279) whereas post-procedural LVEF was higher in
women than in men (56.8  12.1 vs. 51.0  12.7, p 
.001), as it was before TAVI. No significant difference
as observed in post-procedural aortic regurgitation 2
34.4% vs. 27.1%, p  0.228). The 30-day mortality was
omparable between women and men (12.2% vs. 17.8%,
 0.207) as was as the 30-day combined safety point
pulation
Female (n  131) Male (n  129) p Value
83.8 5.9 82.4 6.5 0.080
1.65 0.17 1.85 0.16 0.001
25.6 4.8 25.9 4.1 0.539
24 (18.3%) 37 (28.7%) 0.049
53 (40.5%) 73 (56.6%) 0.009
93 (71.0%) 91 (70.5%) 0.937
5 (3.8%) 12 (9.3%) 0.075
113 (86.3%) 107 (82.9%) 0.461
64 (48.9%) 102 (79.1%) 0.001
10 (7.6%) 28 (21.7%) 0.003
33 (25.2%) 46 (35.6%) 0.050
18 (13.7%) 34 (26.4%) 0.011
35 (26.7%) 52 (40.3%) 0.020
13 (9.9%) 20 (15.5%) 0.179
50 (38.2%) 47 (36.4%) 0.774
50.3 23.5 53.6 26.8 0.318
90 (69.2%) 84 (66.1%) 0.598
22.3 9.1 26.2 13.0 0.005
0.59 0.17 0.61 0.13 0.248
0.35 0.10 0.33 0.07 0.037
49.7 19.9 45.5 15.8 0.069
53.5 12.9 47.2 14.6 0.001
26 (19.8%) 51 (39.5%) 0.001
20.9 1.4 22.9 1.7 0.001
33.8 4.1 35.7 4.3 0.002
35 (26.7%) 40 (31.0%) 0.447
0.85 0.73 0.80 0.67 0.532
1.00 0.75 0.95 0.70 0.629
tive pulmonary disease; eGFR estimated glomerular filtration rate;
left ventricular ejection fraction; MImyocardial infarction; NYHAndy Po
obstruc14.5% vs. 20.2%, p  0.231).
emoral
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median follow-up of this cohort was 217 days (interquartile
range: 54 to 401 days). In total, 79 patients (32 female and
47 male) died during the follow-up period.
Although no significant sex differences were observed
with respect to the 30-day mortality rate, women had a
better midterm survival (Fig. 2). Male sex was also identified
as a predictor of midterm mortality by Cox regression
analysis (hazard ratio: 1.62, 95% confidence interval: 1.03 to
2.53, p  0.037) (Table 4).
Procedural Characteristics of the Study PopulatTable 2 Procedural Characteristics of the S
Total (N  26
Edwards 222 (85.4%
Transfemoral 138 (53.1%
Transapical 83 (31.9%
Transsubclavian 1 (0.4%)
CoreValve 38 (14.6%
Transfemoral 31 (11.9%
Transsubclavian 7 (2.7%)
Valve size, mm 25.1 2.0
Local anesthesia 102 (39.2%
Sheath size, F 22.0 3.4
Introducer sheath diameter, mm 7.72 0.83
Femoral artery MLD, mm 8.12 1.25
SFAR 0.99 0.16
Femoral artery calcification score (0–3) 0.56 0.69
Femoral artery tortuosity score (0–3) 0.29 0.55
Values are n (%) or mean  SD.
MLD  minimal lumen diameter; SFAR  sheath outer diameter/f
Post-Procedural Complications and OutcomesTable 3 Post-Procedural Complications and
Total (N  260
Transfusion 4 U 19 (7.3%)
Local infection 9 (3.5%)
Major vascular complication 27 (10.4%)
In-hospital acute MI 2 (0.8%)
In-hospital cerebrovascular accident 4 (1.7%)
Cardiac tamponade 5 (1.9%)
Annulus rupture 3 (1.2%)
Valve migration 8 (3.1%)
Conversion to open heart surgery 7 (2.7%)
Post-implantation
Mean pressure gradient, mm Hg 11.2 4.9
LVEF, % 53.9 12.7
LVEF change, % 3.7 11.0
Aortic regurgitation (0–4) 1.15 0.84
Aortic regurgitation 2 80 (30.8%)
Aortic regurgitation 3 11 (4.2%)
Mitral regurgitation (0–4) 1.01 0.82
New pacemaker 17 (6.5%)
Device success 233 (89.6%)
30-day mortality 39 (15.0%)
30-day combined safety point 45 (17.3%)
Hospital stay, days 11.6 8.6Values are n (%) or mean  SD.
LVEF  left ventricular ejection fraction; MI  myocardial infarction.Discussion
This study provides the first precise description of sex-
related differences in patients with severe AS undergoing
TAVI using both the Edwards valve and the CoreValve.
Female sex was associated with lower comorbidities and a
lower EuroSCORE. Although no significant relationship
with 30-day mortality was evidenced, female sex was asso-
ciated with better midterm survival and also identified as a
predictor of midterm survival.
Population
Female (n  131) Male (n  129) p Value
120 (91.6%) 102 (79.1%) 0.005
80 (61.1%) 58 (45.0%) 0.125
39 (29.8%) 44 (34.1%)
1 (0.8%) 0
11 (8.4%) 27 (20.9%) 0.005
10 (7.6%) 21 (16.3%) 0.346
1 (0.8%) 6 (4.7%)
23.9 1.6 26.3 1.5 0.001
56 (42.7%) 46 (35.7%) 0.243
21.6 3.3 22.3 3.5 0.090
7.28 0.55 8.15 0.80 0.001
7.74 1.03 8.55 1.34 0.001
1.02 0.14 0.96 0.17 0.015
0.37 0.57 0.77 0.75 0.001
0.26 0.49 0.33 0.61 0.442
artery ratio.
omes
Female (n  131) Male (n  129) p Value
8 (6.1%) 11 (8.5%) 0.453
5 (3.8%) 4 (3.1%) 0.752
15 (11.5%) 12 (9.3%) 0.570
1 (0.8%) 1 (0.8%) 0.991
1 (0.8%) 3 (2.3%) 0.306
3 (2.3%) 2 (1.6%) 0.664
2 (1.5%) 1 (0.8) 0.509
4 (3.1%) 4 (3.1%) 0.982
4 (3.1%) 3 (2.3%) 0.718
11.6 4.9 10.9 4.9 0.279
56.8 12.1 51.0 12.7 0.001
3.4 10.6 4.0 11.5 0.680
1.17 0.85 1.12 0.83 0.636
45 (34.4%) 35 (27.1%) 0.228
4 (3.1%) 7 (5.4%) 0.261
1.15 0.85 0.89 0.77 0.017
7 (5.9%) 10 (7.8%) 0.432
119 (90.8%) 114 (88.4%) 0.516
16 (12.2%) 23 (17.8%) 0.207
19 (14.5%) 26 (20.2%) 0.231
11.6 9.2 11.6 8.0 0.980iontudy
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Sex-Related Differences in TAVI February 7, 2012:566–71In our study cohort, the mean age was higher (83.1 6.3
years) compared with that of previously reported series of
SAVR (1,4) because of the nature of the TAVI procedure
implemented for inoperable or high-risk elderly patients.
Women had a lower rate of comorbidity such as coronary
artery disease and peripheral artery disease, and higher
LVEF. These findings were comparable with previously
published SAVR data (1,4). Smaller bioprosthesis sizes were
selected for women than for men (23.9 1.6 vs. 26.3 1.5,
 0.001) because of women’s smaller aortic annulus size
20.9  1.4 vs. 22.9  1.7, p  0.001). This is consistent
ith existing SAVR reports (4,5).
A clear difference between TAVI and SAVR was found in
he logistic EuroSCORE. In general, female patients under-
oing SAVR are of more advanced age and have a higher
ogistic EuroSCORE (1,4). However, this score was signifi-
antly lower in women than in men (22.3  9.1 vs. 26.2 
3.0, p  0.005), presumably due to less comorbidity.
Although there was no significant difference in the
0-day mortality rate, female sex was associated with better
idterm survival, and Cox regression analysis identified
ale sex as a predictor of midterm mortality (hazard ratio:
.62, 95% confidence interval: 1.03 to 2.53, p  0.037).
Several contrasting reports on sex-related differences
n SAVR have been published (4,5,11). In female patients,
AVR is technically demanding because of their smaller
tature, BSA, and aortic root. These characteristics may
artly explain their higher 30-day mortality rate with SAVR
5,11). In our study cohort, TAVI in female patients was
uccessfully performed with a device success rate similar to
hat of male patients (90.8% vs. 88.4%, p  0.516), because
f the higher procedural feasibility inherent in this novel
echnique, despite the specific characteristics associated with
Figure 2 Impact of Sex on Midterm Survival
Although no significant sex differences were observed with respect to the
30-day mortality rate, female patients (solid line) had a better midterm survival
compared to male patients (broken line) (p  0.037).eing female.Prosthesis-patient mismatch, resulting in a persistent
bnormally high transvalvular gradient, also remains an
mportant issue for SAVR in females because of their
maller aortic annulus, limiting the prosthesis size. It has
lso been reported as an independent predictor of operative
ortality in several studies of SAVR (12,13).
In our TAVI cohort, excellent hemodynamic perfor-
ance was achieved for both women and men, with a low
ean aortic pressure gradient at discharge (11.6  4.9 vs.
0.9  4.9, p  0.279), even with smaller prostheses in
omen. Furthermore, no significant differences were ob-
erved in post-procedural aortic regurgitation2 (34.4% vs.
7.1%, p  0.228). One study describing sex-related dif-
erences in SAVR showed a significantly higher survival rate
or female patients, especially for those 79 years of age,
hereas there was no significant difference among patients
79 years of age (4). Our TAVI study cohort had similar
ean age, and its data were comparable with those of
AVR in patients of advanced age. The higher survival rate
an be explained by women’s longer life expectancy and is
lso influenced by a lower rate of comorbidity, as attested to
y a lower EuroSCORE. Given the impact of confounding
actors, the influence of sex on outcome may be of only
orderline significance.
tudy limitations. Our study reports results achieved in a
ingle-center TAVI cohort consisting of a limited number
f patients recruited in the initial phase of our experience
ith this new technology. Multivariate analysis was not
erformed because of the low endpoint count. Further
tudies of larger patient populations are required to confirm
ur results.
Predictors for Midterm Mortalityby Cox Regression AnalysisTable 4 Predictors for Mid erm Mortalityby Cox Regression Analysis
Variables p Value
Hazard
Ratio 95% CI
Male 0.037 1.62 1.03–2.53
Experience 0.023 1.73 1.08–2.78
Logistic EuroSCORE 0.027 1.02 1.00–1.04
Post-procedural aortic regurgitation 2 0.009 1.97 1.19–3.28
Transfusion 4 U 0.001 4.66 2.39–9.09
Acute kidney injury 0.001 4.88 2.49–9.56
Conversion to open heart surgery 0.001 7.51 3.18–17.76
Periprocedural cerebrovascular accident 0.001 5.46 1.98–15.06
Major vascular complication 0.008 2.12 1.21–3.70
Age 0.67 1.01 0.97–1.05
Body surface area, m2 0.68 0.78 0.24–2.50
Body mass index, kg/m2 0.30 0.97 0.92–1.03
Coronary artery disease 0.19 1.38 0.85–2.23
COPD 0.12 1.42 0.91–2.21
LVEF 40% 0.40 1.22 0.77–1.95
Type of TAVI 0.88 1.05 0.56–1.99
Transapical approach 0.32 1.27 0.80–2.02
Transsubclavian approach 0.46 2.10 0.29–15.1
Valve migration 0.09 2.24 0.89–5.61
Univariate analysis was used to identify the predictors.
CI  confidence interval; TAVI  transcatheter aortic valve implantation; other abbreviations as
in Table 1.
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February 7, 2012:566–71 Sex-Related Differences in TAVIConclusions
Female sex was associated with fewer comorbidities and a
lower EuroSCORE. Despite women having smaller body,
and femoral, aorta, and aortic annulus size, similar device
success was achieved in women and men alike with an
adequate reduction in the transprosthetic pressure gradient.
Although no relation with the 30-day mortality rate was
observed, female sex was associated with better midterm
survival after TAVI.
Acknowledgment
The authors thank Mrs. Catherine Dupic for her assistance
in the preparation of this manuscript.
Reprint requests and correspondence: Dr. Marie-Claude
Morice, Institut Hospitalier Jacques Cartier, 6 Avenue du Noyer
Lambert, Massy 91300, France. E-mail: mc.morice@icps.com.fr.
REFERENCES
1. Morris JJ, Schaff HV, Mullany CJ, Morris PB, Frye RL, Orszulak TA.
Gender differences in left ventricular functional response to aortic valve
replacement. Circulation 1994;90:II183–9.
2. Kulik A, Lam BK, Rubens FD, et al. Gender differences in the
long-term outcomes after valve replacement surgery. Heart 2009;95:
318–26.
3. Doenst T, Ivanov J, Borger MA, David TE, Brister SJ. Sex-specific
long-term outcomes after combined valve and coronary artery surgery.
Ann Thorac Surg 2006;81:1632–6.4. Fuchs C, Mascherbauer J, Rosenhek R, et al. Gender differences in
clinical presentation and surgical outcome of aortic stenosis. Heart
2010;96:539–45.
5. Caballero-Borrego J, Gomez-Doblas JJ, Valencia-Serrano FM, et al.
Influence of sex on perioperative outcomes in patients undergoing
valve replacement for severe aortic stenosis. Rev Esp Cardiol 2009;62:
31–8.
6. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve
implantation for aortic stenosis in patients who cannot undergo
surgery. N Engl J Med 2010;363:1597–607.
7. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint
definitions for transcatheter aortic valve implantation clinical trials a
consensus report from the valve academic research consortium. J Am
Coll Cardiol 2011;57:253–69.
8. Hayashida K, Lefevre T, Chevalier B, et al. Transfemoral aortic valve
implantation: new criteria to predict vascular complications. J Am Coll
Cardiol Intv 2011;4:851–8.
9. Webb JG, Pasupati S, Humphries K, et al. Percutaneous transarterial
aortic valve replacement in selected high-risk patients with aortic
stenosis. Circulation 2007;116:755–63.
10. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve
replacement for severe aortic stenosis in high-risk patients using the
second- and current third-generation self-expanding CoreValve pros-
thesis: device success and 30-day clinical outcome. J Am Coll Cardiol
2007;50:69–76.
11. Edwards FH, Peterson ED, Coombs LP et al. Prediction of operative
mortality after valve replacement surgery. J Am Coll Cardiol 2001;37:
885–92.
12. Walther T, Rastan A, Falk V et al. Patient prosthesis mismatch affects
short- and long-term outcomes after aortic valve replacement. Eur
J Cardiothorac Surg 2006;30:15–9.
13. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P.
Impact of valve prosthesis-patient mismatch on short-term mortality
after aortic valve replacement. Circulation 2003;108:983–8.Key Words: aortic stenosis y mortality y sex differences y transcatheter
aortic valve implantation y Valve Academic Research Consortium.
